On the heels of Novavax receiving $1.6 billion in federal aid for its COVID-19 vaccine candidate, the author of today’s article advises that “investors might find opportunities in biotechnology stocks that have high financial strength, earnings yield and return on capital” – and he highlights five top stocks in this regard that pass a “magic formula” screen and have the backing of investing gurus. For more, CLICK HERE.